Novartis Ag (NVSEF) Notes Payables (2017 - 2025)

Novartis Ag has disclosed Notes Payables across 9 years of filings, most recently posting $682.0 million for Q4 2025.

• Notes Payables for Q4 2025 came in at $682.0 million, up 6.23% year-over-year; the trailing twelve-month figure through Dec 2025 was $682.0 million (up 6.23% YoY), and the FY2025 annual result was $682.0 million, up 6.23% from the prior year.
• Notes Payables came in at $682.0 million for Q4 2025 at Novartis Ag, up from $642.0 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $899.0 million in Q4 2021 to a low of $624.0 million in Q4 2023.
• The 5-year median for Notes Payables is $682.0 million (2025), against an average of $742.0 million.
• Across the five-year window, Notes Payables dropped 27.69% in 2023 and gained 6.23% in 2025, its largest moves.
• Novartis Ag's Notes Payables stood at $899.0 million in 2021, then slipped by 4.0% to $863.0 million in 2022, then slipped by 27.69% to $624.0 million in 2023, then rose by 2.88% to $642.0 million in 2024, then advanced by 6.23% to $682.0 million in 2025.
• The last three Notes Payables figures came in at $682.0 million (Q4 2025), $642.0 million (Q4 2024), and $624.0 million (Q4 2023), per Business Quant data.